Artivion announces presentations of clinical data from Nexus and AMD trials

Artivion (AORT) announced the presentation of new clinical data from Endospan’s NEXUS TRIOMPHE IDE trial and its AMDS PERSEVERE IDE trial at the 62nd Annual Meeting of the Society of Thoracic Surgeons in New Orleans, Louisiana. The NEXUS TRIOMPHE IDE trial presentation of 94 patients highlighted 94% patient survival from lesion related death and 91% freedom from disabling stroke at 1-year post-treatment in this high-risk patient group. The data also showed 97% of patients were free from reintervention due to endoleaks with no occurrence of renal failure and one occurrence of paraplegia out to 1-year post-implant. Meanwhile, data from the AMDS PERSEVERE IDE trial demonstrated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry, or DANE, tears between 1- and 2-year follow-up. The abstract titled “An Off the Shelf Solution for Chronic Dissections Involving the Aortic Arch: One Year Results of the NEXUS Aortic Arch System” reports 1-year of clinical follow-up on all 94 enrolled patients who were treated with NEXUS for chronic dissection, aneurysm, or other arch disease. The abstract titled “Using a Novel Hybrid Aortic Arch Prosthesis for Open Repair of Acute DeBakey Type I Dissection with Malperfusion: Two-Year Results from the PERSEVERE Trial” reports noteworthy clinical and radiographic outcomes on 93 study participants following 1- and 2-year of clinical and radiographic follow-up.